Trial Profile
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Ceralifimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms DreaMS
- Sponsors Ono Pharmaceutical
- 23 Mar 2013 Results using the more sensitive statistical method presented at the 65th Annual Meeting of the American Academy of Neurology.
- 13 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 28 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology.